Skip to ContentSkip to Navigation
Over onsMedische WetenschappenResearchDepartment of GeneticsStaff
University Medical Center Groningen

Jeantine Lunshof, PhD

Assistant professor, filosoof/ethicus
Jeantine Lunshof
Jeantine Lunshof

Studies: BA, 1977, in Philosophy, minor in Tibetan language & cutural studies, Hamburg University, Germany
RN, 1981, St. Elisabeth Hospital, Haarlem, Netherlands
MA, 1988, in Philosophy (Systemic Philosophy, Ethics, Medical Ethics) and Health Law, University of Amsterdam (UvA), Netherlands

PhD thesis: The new genomics: challenges for ethics, VU University Amsterdam, 2008. Thesis available here


See all my papers in PubMed or in GoogleScholar

Keywords: philosophy, ethics, bioethics, genomics, systems genetics, biobanking, pharmacogenomics, systems biology, synthetic biology, biological engineering, ecosystems


August 2, 2017: Adaptive risk management of gene drive experiments: biosafety, biosecurity, and ethics

by Jeantine Lunshof and Angela Birnbaum, in Applied Biosafety, Sage Publications, full article freely available until 31st August
Abstract: Emerging technologies in the life sciences call for new models of biosafety risk management. We examine the question of how to address new developments in the life sciences and biosciences in a bottom-up manner—that is, from the concrete level of biosafety practice with a focus on the risk management and risk assessment of emerging technologies in the biology laboratory. We use research on “gene drives” as an example of challenging work with new constructs that have major biosafety implications for the work in the laboratory and beyond. Gene drives are intended for use in ecosystems and require, at an early stage, the consideration of potential future biosafety, biosecurity, and societal impact. We argue for an integrative approach, a truly collaborative model that involves scientists, biosafety officers, institutional leadership, and ethics consultants, with the aim of maximizing safety as well as scientific progress.

April 18, 2017: Artikel in de Volkskrant

Deze bio-ethicus staat Amerikaanse kloonwetenschappers bij Een discussie met bio-ethicus Jeantine Lunshof over drie intrigerende experimenten vanuit een ethische invalshoek.

April 7, 2017: An unbiased index to quantify participant’s phenotypic contribution to an open-access cohort

This paper describes a bioinformatic approach to quantifying the phenotypic data collected by the Personal Genome Project, an open public access repository of genotype and phenotype data where participants contribute their own phenotypic information. Scientific Reports 2017;7:46148. doi:10.1038/srep46148

April 1, 2017: Artikel in de NRC Handelsblad

Genetische verandering in een hogere versnelling Biotechnologen kunnen het DNA van een organisme zó veranderen dat het een bepaalde eigenschap bijna altijd doorgeeft aan het nageslacht. Zo kun je ziekten bestrijden.

March 21, 2017: Addressing the ethical issues raised by synthetic human entities with embryo-like features

In this new paper authors John Aach, Jeantine Lunshof, Eswar Iyer and George M Church call for the development of guidelines to address the ethics of experimenting on synthetic human tissue that shows traces of early embryonic development. See Harvard Medical School press release for more information. eLife 2017;6:e20674

February 23, 2017: In a lab pushing the boundaries of biology, an embedded ethicist keeps scientists in check

Interview in STAT. "Rapid advances in genomics and stem cell biology are forcing researchers to regularly confront ethical quandaries that seem straight out of science fiction" and "There is essentially no limit to the technology, so we need to focus on the ethics and the humanity” as guides to how far to take the science."

January 2017 : Interview on The ethical implications of the use of genetic engineering for the elimination Lyme disease

Luister naar interview in het nederlands, NOS radio 1 (8 mins) over de Greenwall project hier, zie ook artikel over gene drives in NRC (in nederlands)

Since January 2017 I am leading a bioethics research project that studies the ethical implications of the use of novel genetic engineering methods for the elimination of Lyme disease. This project is a unique collaboration with Professor Kevin Esvelt from the MIT Media Lab. Our project receives funding from the Greenwall Foundation, in the program ‘Making a Difference in Real-World Bioethics Dilemmas’. The project works in parallel with genetic engineering research that aims at ‘immunizing’ mice against Borrelia burgdorferi and/or tick saliva in order to prevent the transmission of tick-borne pathogens for which the mouse is a reservoir (see press release). Here, genome editing is used to alter an ecosystem. Such interventions in the shared space of the environment can only be initiated if acceptable to the communities involved. But, what does ‘acceptable’ mean? By what process should communities and scientists jointly make decisions from the earliest stages of project planning? Our project entitled “A mutually responsive approach to developing technologies that alter shared ecosystems” will develop a model that can serve as the normative backbone of Responsive Science. Zie ook Persbericht in nederlands

The Genome Project-Write – engineering and testing large genomes in cell lines .

Since early 2016 I have been involved as a philosopher/ethicist in the Genome Project-Write.

What is the Genome Project-write?*
The Genome Project-write (HGP-write) will be an open, academic, international scientific research project led by a multi-disciplinary group of scientific leaders who will oversee a reduction in the costs of engineering and testing large genomes, including a human genome, in cell lines by over 1,000-fold within ten years. At the same time they will develop new technologies and an ethical framework for genome-scale engineering as well as transformative medical applications. The overarching goal of such an effort is to further our understanding of the blueprint for life provided by the Human Genome Project (HGP-read).

Who will be involved in HGP-write?
Ultimately, this multi-disciplinary effort will include an international group of biologists, chemists, computational biologists, engineers, social scientists, and ethicists. And, as noted in the Commentary published in Science on June 2, 2016, it will also require public involvement and consideration of social, ethical and legal implications (ELSI) from the start, as well as identifying common goals important to scientists and the wider public through timely and detailed consultation among diverse stakeholders.

Boeke JD, et al. The Genome Project-Write. Science. 2 June 2016

Van zie website voor achtergrond informatie.

Luister naar NOS radio interview, 3 juni 2016, 16:50 (in Dutch)
Minder kanker, ongevoeligheid voor virussen en het kweken van menselijke organen. Het is een greep uit de beloften die wetenschappers en ondernemers deze week doen in het vakblad Science. Ze willen dat doen via het zogenoemde Human Genome Project Write: een controversieel project waarin ze het hele menselijke genoom, het DNA, stukje voor stukje willen opbouwen.
Ethica Jeantine Lunshof is als enige Nederlander bij het project betrokken. Ze is verbonden aan de Rijksuniversiteit Groningen en aan de Harvard Medical School.

On Revision of the Coordinated Framework for the Regulation of Biotechnology . A White Paper Prepared for Consideration by the Biotechnology Working Group - Emerging Technologies Interagency Policy Coordination Committee.  2016. Oye KE, et al.
Novel methods in high-precision genome editing open up a wide range of potential applications that do not neatly fit into current regulatory structures. Gene drives – genomic tools for interventions in wild species populations – are one such novel application. In the US, the so-called Coordinated Framework assigns regulatory tasks to the relevant agencies. The need for a revision of the Coordinated Framework and its policies has led to a call for recommendations, in response to which the Synthetic Biology Policy Group of the Program on Emerging Technologies (PoET) at MIT, led by Professor Ken Oye, has prepared a White Paper with suggestions. As a Marie Curie Fellow, and as ethics consultant to the Church lab and group member of PoET, I have been involved with both the science and the normative questions surrounding CRISPR-based genome editing and in particular the development of the combination of CRISPR edits with gene drives. See my recent Worldview in Nature for more background on gene drives. More information can be found at

Mijn achtergrond: ik ben filosoof, ethicus en heb gezondheidsrecht gestudeerd. Mijn speciale werkgebied is genetica/genomics, sinds ik daar in 1988 als ethisch adviseur van de VSOP in terecht kwam. Ik heb vele jaren in Duitsland gewerkt, in het Institut für Humangenetik in Heidelberg en in diverse andere projecten. Sinds 2006 ben ik Ethics Consultant van het Personal Genome Project, PGP (, onder leiding van George Church in het Department of Genetics, Harvard Medical School, Boston. Samen met George Church en de jurist Dan Vorhaus ontwikkelde ik in 2007 een nieuw model voor research consent. Dit is het ‘Open Consent’ dat we gebruiken om PGP deelnemers complete en ‘valide’ consent te kunnen laten geven voor het doneren van hun data in een publieke, open access databank. Het Personal Genome Project belooft geen anonimiteit of vertrouwelijkheid, biologische informatie is immers altijd herleidbaar tot het individu.

In 2012-2014 heb ik twee jaar aan mijn trainings- en onderzoeksproject ‘Systems|Networks|Norms (SysNorm)’ gewerkt als Marie Curie Fellow in het Church lab. De centrale vraag van het project is of systeem-biologische en network concepten tot nieuwe modellen in de ethiek leiden. Ik kijk daarom naar de extreme snelle vooruitgang in de genomic sciences en de technologie-ontwikkeling. Genomic sciences omvatten ook synthetische biologie toepassingen als CRISPR-Cas9 voor genome editing, inmiddels mogelijk in een groot aantal organismen. Daar ligt een breed veld voor filosofische en ethische vragen!

Een genome editing toepassing die veel normatieve aspecten behelst (ethische, juridische en ook governance) is de recente ontwikkeling van ‘gene drives’ voor ecosystem management door beïnvloeding van wilde populaties. Een voorbeeld is de verandering van malariamuggen om ze als vector uit te schakelen. Ik werk hierin samen met researchers in het MIT Program on Emerging Technologies en in het Wyss Institute for Biologically Inspired Engineering. Zie Driving change, editing genomes

Vanaf januari 2015 was ik Marie Curie Fellow in afdeling Genetica in UMC Groningen. Nu als assistent professor werk ik verder aan de diverse thema’s en kijk uit naar de samenwerking met de experts daar in Systems Genetics. Ik werk graag samen aan andere vragen, zoals de concrete toepassing van de nieuwste sequencing methoden in de klinische praktijk en de diverse aspecten van grootschalig genoomonderzoek.

Selected Publications

See all my papers in PubMed or in GoogleScholar

An unbiased index to quantify participant’s phenotypic contribution to an open-access cohort. Chan Y, Tung M, Garruss AS, Zaranek SW, Chan YK, Lunshof JE, Zaranek AW, Ball MP, Chou MF, Lim ET & Church GM. Scientific Reports 2017;7:46148. doi:10.1038/srep46148

Addressing the ethical issues raised by synthetic human entities with embryo-like features Aach J, Lunshof J, Iyer E & Church GM eLife 2017;6:e20674. doi: 10.7554/eLife.20674

GENOME ENGINEERING. The Genome Project-Write. Boeke JD, Church G, [...] Lunshof J, [...] Way JC, Yang L. Science 2016;353:126-127. doi:10.1126/science.aaf6850

On Revision of the Coordinated Framework for the Regulation of Biotechnology A White Paper Prepared for Consideration by the Biotechnology Working Group - Emerging Technologies Interagency Policy Coordination Committee. January 20, 2016, Cambridge, MA, USA

Human germ line editing—roles and responsibilities Lunshof JE, Commentary. Protein Cell 2016:7:7-10

Regulate gene editing in wild animals JE Lunshof, Nature 2015;521:127

Barash CI, Lunshof JE. Reciprocity and transparency: Normative principles of data sharing. Applied & Translational Genomics 2014;3:122-123

Kevin Esvelt, George Church and Jeantine Lunshof. “Gene Drives” and CRISPR Could Revolutionize Ecosystem Management. Scientific American, Guest blog, July 17 2014

Lunshof J, Chadwick R. Genomics, inconvenient truths and accountability. In: Chadwick R, Levitt M, Shickle D (Eds). The Right to Know and the Right Not to Know – Genetic Privacy and Responsibility. Cambridge University Press, 2014

Ball MP, Bobe JR, Chou MF, Clegg T, Estep PW, Lunshof JE, Vandewege W, Zaranek A, Church GM. Harvard Personal Genome Project: lessons from participatory public research. Genome Med 2014;6:10

Lunshof JE, Church GM, Prainsack B. Raw personal data: providing access. Science 2014;343:373-374

Jeantine E. Lunshof. Whole genomes, small children, big questions. Personalized Medicine 2012;9:667-669

Ball MP, Thakuria JV, Zaranek AW, Clegg T, Rosenbaum AM, Wu X, Angrist M, Bhak J, Bobe J, Callow MJ, Cano C, Chou MF, Chung WK, Douglas SM, Estep PW, Gore A, Hulick P, Labarga A, Lee JH, Lunshof JE, Kim BC, Kim JI, Li Z, Murray MF, Nilsen GB, Peters BA, Raman AM, Rienhoff HY, Robasky K, Wheeler MT, Vandewege W, Vorhaus DB, Yang JL, Yang L, Aach J, Ashley EA, Drmanac R, Kim SJ, Li JB, Peshkin L, Seidman CE, Seo JS, Zhang K, Rehm HL, Church GM. A public resource facilitating clinical use of genomes. Proc Natl Acad Sci USA 2012;109(30):11920-11927

Kolodkin A, Boogerd FC, Plant N, Bruggeman FJ, Goncharuk V, Lunshof J, Moreno-Sanchez R, Yilmaz N, Bakker BM, Snoep JL, Balling R, Westerhoff HV. Emergence of the silicon human and network targeting drugs. Eur J Pharm Sci 2012;46:190-197

Becla L, Lunshof JE, Gurwitz D, Schulte In den Bäumen T, Westerhoff HV, Lange BM, Brand A. Health technology assessment in the era of personalized health care. Int J Tech Assessment in Health Care 2011;27(2):118-26

JE Lunshof, R Chadwick. Editorial. Genetic and Genomic Research – Changing Patterns of Accountability.  Accountability in Research 2011;18(3):121-131. Guest Editor Special Issue: Impact of Genomics Research on Ethical Issues.

Jeantine E Lunshof, Jason Bobe, John Aach, Misha Angrist, Joseph V Thakuria, Daniel B Vorhaus, Margret R Hoehe, George M Church. Personal genomes in progress: from the Human Genome Project to the Personal Genome Project. Dialogues in Clinical Neuroscience 2010;12:47-60

David Gurwitz, Isabel Fortier, Jeantine E. Lunshof and Bartha Maria Knoppers. Children and Population Biobanks. Science 2009;325:818-819

Barbara Prainsack, Jenny Reardon, Richard Hindmarsh, Herbert Gottweis, Ursula Naue & Jeantine E. Lunshof. Misdirected precaution. Nature 2008;456:34-35.

Jeantine E. Lunshof. The new genomics and personal genome information: ethical issues. In M. Janitz (Ed.) Next Generation Genome Sequencing. Wiley-VCH, Weinheim. 2008;245-254

Jeantine E Lunshof, Ruth Chadwick, Daniel B. Vorhaus and George M. Church. From genetic privacy to open consent. Nature Reviews Genetics 2008;9:406-411

Jeantine E. Lunshof, Ruth Chadwick, George M. Church. Hippocrates revisited? Old ideals and new realities. Genomic Medicine 2008;2:1-3. pdf

Gurwitz D, Lunshof JE, Altman RB. A Call for the Creation of Personalized Medicine Databases. Nature Reviews Drug Discovery 2006;5:23-26

G Church, J Lunshof, D Vorhaus. “White Paper” on Informed Consent Protocols. August 2006 (NIH/NHGRI); November 2006, publicly available

JE Lunshof. Personalized medicine: how much can we afford? A bioethics perspective. Personalized Medicine 2005;2(1):43-47

Laatst gewijzigd:03 augustus 2017 10:51
printOok beschikbaar in het: English